Concepedia

COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway

K. Salim, Saman Maleki Vareki, Wayne R. Danter, James Koropatnick

European Journal of Cancer · 2016 · 23 citations · 0 references

DOI

Concepts